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Objective: To investigate whether cost-related non-
collection of prescription medication is associated with
a decline in health.
Settings: New Zealand Survey of Family, Income and
Employment (SoFIE)-Health.
Participants: Data from 17 363 participants with at
least two observations in three waves (2004–2005,
2006–2007, 2008–2009) of a panel study were
analysed using fixed effects regression modelling.
Primary outcome measures: Self-rated health
(SRH), physical health (PCS) and mental health scores
(MCS) were the health measures used in this study.
Results: After adjusting for time-varying confounders,
non-collection of prescription items was associated
with a 0.11 (95% CI 0.07 to 0.15) unit worsening in
SRH, a 1.00 (95% CI 0.61 to 1.40) unit decline in PCS
and a 1.69 (95% CI 1.19 to 2.18) unit decline in MCS.
The interaction of the main exposure with gender was
significant for SRH and MCS. Non-collection of
prescription items was associated with a decline in
SRH of 0.18 (95% CI 0.11 to 0.25) units for males and
0.08 (95% CI 0.03 to 0.13) units for females, and a
decrease in MCS of 2.55 (95% CI 1.67 to 3.42) and
1.29 (95% CI 0.70 to 1.89) units for males and
females, respectively. The interaction of the main
exposure with age was significant for SRH. For
respondents aged 15–24 and 25–64 years, non-
collection of prescription items was associated with a
decline in SRH of 0.12 (95% CI 0.03 to 0.21) and 0.12
(95% CI 0.07 to 0.17) units, respectively, but for
respondents aged 65 years and over, non-collection of
prescription items had no significant effect on SRH.
Conclusion: Our results show that those who do not
collect prescription medications because of cost have
an increased risk of a subsequent decline in health.
INTRODUCTION
Since the Rand study in the 1980s, it has been
clear that prices significantly affect consump-
tion of healthcare, including medicines,1
even in countries that have generous drug
coverage.2–5 Increasing charges for prescrip-
tion medicines and/or cost barriers to collect-
ing prescription medication have been
associated with lower rates of use,6–9 lower
prescription medicine compliance,6 more fre-
quent discontinuation6 and increased use of
health services among some groups.6 8
Less is known about the extent to which
cost-related restriction of medications is asso-
ciated with adverse health outcomes. The evi-
dence is limited to cross-sectional studies of
selected groups, such as elderly persons and
welfare recipients,8 the elderly,10 adults with
disabilities,11 older adults with diabetes,12 13
Medicare beneficiaries14 and indigent
patients with heart disease.15 Since these
are cross-sectional in design, they are
susceptible to unmeasured confounding bias.
Developing a better understanding of the
impact of non-collection or deferral of pre-
scription medication requires longitudinal
data on prescription medication deferral and
health. One of the few studies to explore the
longitudinal relationship between cost-
related deferral of prescription medicines
and health showed that, for middle-aged and
elderly Americans, deferral led to poorer
self-rated health (SRH) and higher rates of
Strengths and limitations of this study
▪ A panel study design and a large sample of the
adult population.
▪ Use of fixed effects regression, which controls
for all unmeasured time-invariant and known
time-varying confounders.
▪ Use of multiple measures of health outcome.
▪ Violation of fixed effects assumptions and meas-
urement errors in self-reported health measures
▪ Residual selection bias due to attrition of respon-
dents from the survey.
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some cardiovascular events among those with existing
cardiovascular disease.16 This group was also more likely
to be hospitalised within 2 years of reported prescription
deferral.17 However, Heisler et al16 focused on adults
aged 51–61 and 70 years or older, and had a relatively
short follow-up period (2–3 years). Their study also had
methodological limitations, such as not accounting for
time-invariant unmeasured confounding or serial
correlation.
Apart from being cross-sectional, much of the research
on the impact of prescription charges has been carried
out in the USA, where people pay large amounts for pre-
scription medicines, particularly if they are uninsured or
underinsured. Even people covered by the Medicare
Prescription Drug Benefit (known as Part D) pay signifi-
cant amounts for prescription medicines and there is a
coverage gap.18 In countries with public health systems,
prescription charges are generally lower, and those on
low incomes and/or with high healthcare needs are
often exempted.4 In the UK, prescriptions are free of
charge in Wales, Ireland and Scotland, whereas in
England, people under 16 or over 60 years of age, or
those dependent on government benefits, receive free
prescriptions.19 20 In New Zealand, prescription charges
are low (NZ$3.00 (£1.46) during the study and currently
NZ$5.00 (£2.43) per item) but only children under
6 years of age are currently exempted. There is evidence
that even these low charges lead to cost-related defer-
ral,21 but it is not known whether this deferral leads to
poor health outcomes. Although it is likely that increases
in relatively high initial prices (such as in the USA)
could lead to people deferring medicines that are
crucial for maintaining health, there is no evidence
about whether increases in relatively low prices might
have the same effect.
In this study, we examine the association of cost-
related non-collection of prescription medication with
health status, using a national panel study of adult New
Zealanders. We used fixed effects analyses that remove
all observed and unobserved time-invariant confound-
ing, allowing a more robust assessment of causal associa-
tions than is possible with non-repeated-measures data.
We hypothesise that after adjusting for demographic,
socioeconomic and behavioural factors, and accounting
for unmeasured time-invariant confounders (unob-
served fixed characteristics of individuals such as intelli-
gence or beliefs that are likely to be associated with both
deferral and health), those who do not collect one or
more prescription medications would be more likely to




This research used data from three waves of the
SoFIE-Health survey, which is an add-on to the Statistics
New Zealand Survey of Family, Income and Employment
SoFIE V.2, Waves 1–7.22 SoFIE is an 8 year (2002–2010)
longitudinal household panel survey. Computer-assisted
face-to-face interviews were used to collect data annually
on income levels and sources, and on the major influ-
ences on income such as employment and education,
household and family status, demographic factors and
health status.
The population covered by SoFIE includes those living
in private dwellings, and excludes people living in insti-
tutions or establishments such as boarding houses and
rest homes. The initial SoFIE sample comprised approxi-
mately 11 500 responding private households (response
rate 83%) with 22 200 adults (aged 15 years and above)
responding in wave 1, reducing to just over 20 000 in
wave 2 (91% of wave 1 responders) and over 19 000 in
wave 3 (86% of wave 1 responders). By wave 7, there
were almost 17 000 (76% of wave 1) from the original
sample still participating. Higher rates of attrition
occurred in youth, ethnic minorities, and people on
lower income and reporting poor health.23 On average,
17 377 respondents contributed information to this ana-
lysis from at least two waves.
The SoFIE-Health add-on is comprised of 20 min of
questionnaire time in waves 3 (2004–2005), 5 (2006–
2007) and 7 (2008–2009), in the following health-related
domains: SF-36 (Short-Form health survey), Kessler-10
(K-10), perceived stress,24 chronic conditions (heart
disease, diabetes and injury-related disability), tobacco
smoking, alcohol consumption, access and continuity of
primary health care and an individual socioeconomic
deprivation score.
Measures
The main exposure, not collecting a prescription, was
measured by the following question: “In the past
12 months, have there been any times when a doctor
gave you a prescription, but you did not collect one or
more of these items because you could not afford the
cost? If yes, how many times have you done this in the
last 12 months?”. We dichotomised responses into collec-
tion/non-collection (or not deferred/deferred) for each
of waves 3, 5 and 7.
The three health outcome measures used in this study
are all derived from the SF-36 questionnaire. The SF-36
is one of the most widely used self-completion measures
of health status,25 has been validated for the detection
of changes in health over time26 and is considered to be
reliable for use in the NZ population.27 It consists of 36
questions about the health-related quality of life of
respondents. These are formed into eight domains of
health, which are then used to create two
psychometrically-based physical and mental health
summary measures: the Physical Component Summary
(PCS) and the Mental Component Summary (MCS)
score.28 The PCS and MCS vary between 0 (worst
health) and 100 (best health) and are standardised to
the NZ population, with a mean of 50 and a SD of 10.
Both PCS and MCS were modelled as continuous
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outcomes in regression analyses. A score of 100 in phys-
ical functioning indicates an ability to perform all activ-
ities without limitations due to health; whereas a score
of 100 in mental health indicates an ability to function
without personal or emotional problems. Global SRH
was based on the question: “In general, would you say
your health is: excellent, very good, good, fair, or
poor?”. In this study, SRH was coded to have values
between 1 (excellent health) and 5 (poor health), and,
for consistency with PCS and MCS, was also modelled as
a continuous variable.
Time-varying confounders measured at each wave
were labour force status, marital status, family structure,
NZ Deprivation Index 2001, a measure of small area
deprivation, categorised into quintiles, where quintile 5
corresponds to high deprivation,29 wave (accounting for
the effect of time) and NZiDep, a measure of individual
deprivation.30
Also used in the analysis were the time-invariant cov-
ariates age (at first interview), sex and ethnicity. The eth-
nicity variable was constructed using a ‘prioritised’
definition. Each respondent was assigned to a mutually
exclusive ethnic group by means of a prioritisation
system commonly used in New Zealand: Māori (the indi-
genous people of New Zealand), if any of the responses
to self-identified ethnicity was Māori; Pacific, if any one
response was Pacific but not Māori; Asian, if any one
response was Asian but not Māori/Pacific; the remain-
der non-Māori non-Pacific non-Asian (nMnPnA; mostly
New Zealanders of European descent, but, strictly speak-
ing, not an ethnic group). The reference group was
nMnPnA. Early adulthood is a time of important transi-
tions and the same is true of the period postretirement.
Thus the age covariate was categorised into those under
25 years of age, those between 25–65 years, and those
aged 65 years or above, to see whether these life-course
events impacted on the association between non-
collection of prescriptions and health.
Analyses
Analyses were conducted on an unbalanced panel of eli-
gible wave 1 respondents (17 677) who responded in at
least 2 of waves 3, 5 or 7, and were aged over 15 years.
We hypothesised that the health of those who defer
paying for prescription medication would get worse, and
to determine if this was the case, we computed means
and SDs of health outcomes for respondents who did
not collect a prescription in at least one of 2 or 3 waves.
Transition probabilities for prescription deferral aver-
aged over waves 3, 5 and 7 were computed to show the
typical proportion of SoFIE respondents that changed
prescription collection status between waves.
We modelled health outcomes using a linear fixed
effects model. Such models eliminate variables repre-
senting time-invariant unobserved confounding, mod-
elled as a set of fixed parameters (one for each
respondent), by mean differencing.31 32 Parameter esti-
mates can be interpreted as the response to a 1 unit
change in exposure (continuous exposure) or relative to
the reference group (categorical exposure) considered
contemporaneously.
Fixed effects analysis only uses changes occurring
within the same individuals over time to estimate effects
and ignores observations on variables that do not
change temporally. However, it is possible to fit interac-
tions between time-varying and time-invariant variables
in a fixed effects model. We tested for interactions
between the exposure (prescription collection status)
and age, gender, ethnicity, individual deprivation,
chronic disease/comorbidity status and number of
longitudinal observations for each respondent, to detect
differences between younger and older age groups,
between men and women, between ethnic groups,
between respondents who are more and less deprived,
between respondents who have or do not have a chronic
or comorbid disease, and between respondents with two
or three responses over waves 3, 5 and 7, respectively, in
the association between prescription collection status
and three health outcomes.
All counts presented in this paper are rounded means
of sample counts from waves 3, 5 and 7, and comply
with the Statistics New Zealand protocols for such quan-
tities. Analyses were carried out within the Statistics NZ
data laboratory using the R statistical environment
(http://www.r-project.org) for statistical computation,
V.3.0.1, available from the Comprehensive R archive
Network (CRAN) website (http://cran.r-project.org).
The R package plm V.1.4–0 was used to fit fixed effects
models.
RESULTS
Mean values for the three health outcomes and empir-
ical distributions of covariates are shown in tables 1
and 2 by the proportion of waves where respondents
reported non-collection of a prescription item. For all
outcome measures, health got worse as the proportion of
waves in which non-collection of a prescription item was
reported increased.
Overall, a large majority collected all prescription
items (ie, did not report non-collection of any prescrip-
tion items because of cost) in every wave for which they
responded (table 2), but there were some variations in
this pattern within covariates. For example, relatively
more married respondents collected all prescription
items in every wave (92.1%) than previously married
(87.3%) or never married (87.1%) respondents. Within
levels of family status, the highest proportion of collect-
ing all prescription items in every wave occurred for
couple-only families (95.8%) and the lowest for sole
parents (76.3%). Working and not-working respondents
had similar levels of prescription item collection in every
wave (about 90%). A higher proportion of respondents
from the least deprived (ie, wealthiest) areas collected
all prescription items in every wave (93.1%) than respon-
dents from the most deprived areas (82.5%). Similarly, a
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higher proportion of the least individually deprived (ie,
wealthiest) respondents collected all prescription items
in every wave (96.1%) than the most individually
deprived (50.5%), and relatively more respondents with
degree or higher qualifications collected all prescription
items in every wave (93.8%) than those with no qualifi-
cations (88.3%). Among the time-invariant covariates, a
larger proportion of respondents older than 65 years
collected all prescription items in all waves (98%) than
respondents aged 15–24 years (88.3%), males collected
all prescription items in every wave more often than
females (93.4% and 87.7%, respectively) and Asian
respondents collected all prescription items more often
(93.8%) than European (92.2%), Māori (80.8%) or
Pacific respondents (76.0%). Typically, these patterns
reversed for respondents who did not collect prescrip-
tion items in every wave, though the number of respon-
dents tended to be small in this case.
Empirical transition probabilities between prescription
collection status (collection or non-collection) in succes-
sive waves are provided in table 3. Estimates represent an
average for transitions (in collection states) between
waves 3 and 5, and between waves 5 and 7. Given those
estimates, a respondent who collected all prescription
items over the past 12 months before wave 3 (say) was
very likely to have also collected all prescription items in
the 12 months before wave 5 (average probability
97.4%). In only 2.6% of cases did a respondent collect
all prescription items in the 12 months before wave 3
but not in the 12 months before wave 5. However, a
respondent who did not collect all prescription items in
the 12 months before wave 3 was more likely to collect
all (68.8%) than not collect all (31.2%) prescription
items in the 12 months before wave 5.
Covariate effects for linear fixed effects panel models
with no time-invariant interactions (ie, averaged across
age, gender and ethnicity) for each health outcome are
presented in table 4. Non-collection of prescription
items was associated with a 0.11 (95% CI 0.07 to 0.15)
unit decline in SRH, a 1.00 (95% CI 0.61 to 1.40) unit
decline in PCS and a 1.69 (95% CI 1.19 to 2.18) unit
decline in MCS.
For SRH, interactions of the main exposure with
gender and age were significant. Allowing for those
interactions, non-collection of prescription items was
associated with a decline in SRH of 0.18 (95% CI 0.11 to
0.25) for males and 0.08 (95% CI 0.03 to 0.13) for
females. For respondents aged 15–24 or 25–64 years, the
effect of non-collection of prescription items on SRH
was not significantly different, and was associated with a
decline in SRH of 0.12 (95% CI 0.03 to 0.21) and 0.12
(95% CI 0.07 to 0.17) units, respectively. There was a sig-
nificant difference in the association of non-collection
and SRH for respondents aged 65 years and above (rela-
tive to respondents aged 15–24 years), and, as a result,
non-collection of prescription items had no significant
effect on SRH for this age group. The interaction of the
main exposure with gender was significant for MCS.
Allowing for this, non-collection of prescription items
was associated with a decrease in MCS of magnitude
2.55 (95% CI 1.67 to 3.42) and 1.29 (95% CI 0.70 to
1.89) units, for males and females, respectively.
Interactions of the exposure with age, gender and ethni-
city were not significant for PCS, and interactions of the
exposure with individual deprivation, chronic/comorbid
disease status and the number of observations per
respondent were not significant for any health outcome.
DISCUSSION AND CONCLUSION
Principal findings
First, those who did not collect prescription medications
because of cost, while a relatively small proportion of the
population (less than 10%), had an increased risk of
poorer health. Second, non-collection of prescription
items was associated with significantly poorer SRH and
MCS for males than for females. Third, non-collection
of prescription items was associated with significantly
poorer SRH for respondents aged 15–24 and 25–
64 years, but had no significant effect for respondents
aged 65 years and above. Fourth, these results are net of
all time-invariant confounding.
Strengths and weaknesses
The strengths of the study are the panel study design
based on 18 000 adults, and fixed effects analysis that
removes all time invariant confounding (known or
unknown) and known time-varying confounders (eg,
Table 1 Means and SEs of health outcomes where respondents did not collect one or more prescription items for financial
reasons in at least one of waves 3, 5 and 7, for the unbalanced SoFIE-Health panel
Proportion of waves where one or more prescription items were not collected
100%* 67%† 50%‡ 33%§ 0%¶
SRH 2.805 (0.054) 2.616 (0.037) 2.410 (0.049) 2.431 (0.020) 2.101 (0.005)
PCS 47.501 (0.520) 48.131 (0.370) 50.370 (0.465) 49.675 (0.194) 51.536 (0.044)
MCS 36.072 (0.843) 41.993 (0.521) 43.233 (0.683) 44.451 (0.271) 51.375 (0.047)
*Two non-collections in two waves or three non-collections in three waves.
†Two non-collections in three waves.
‡One non-collection in two waves.
§One non-collection in three waves.
¶No non-collections in two or three waves.
MCS, mental health score; PCS, physical health score; SoFIE, Survey of Family, Income, and Employment; SRH, self-rated health.
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household composition, labour force status). To our
knowledge, this is the first longitudinal study to specific-
ally examine the association between cost-related non-
collection of prescription items and health, net of all
but unknown time-varying confounders. The main limi-
tation with fixed effects analysis is that these models do
not allow for either the effect of current health on
future prescription collection status (reverse causation),
or past health on future health (state dependence),
which violate the strict exogeneity condition required by
fixed effects methods.32 33 Additionally, our analyses may
be affected by selection bias if those who dropped out
from the study reported substantially more or less defer-
ral. However, we found no evidence that exposure–
outcome associations differed between those who con-
tributed information to two or three waves. If those who
dropped out from the study before wave 3 or contribu-
ted to only one of waves 3, 5, or 7 were more likely to
Table 2 Sample counts and proportions for the number of occasions where respondents did not collect one or more
prescription items for financial reasons in at least one of waves 3, 5 and 7, by demographic strata for the unbalanced
SoFIE-Health panel
Proportion of waves where one or more prescription items were not collected/deferred
100%* 67%† 50%‡ 33%§ 0%¶
Total 460 (0.9) 900 (1.8) 490 (10.0) 2885 (5.9) 44 150 (90.3)
Marital status
Never married 135 (1.3) 265 (2.6) 200 (1.9) 745 (7.1) 9080 (87.1)
Previously married 120 (1.6) 195 (2.7) 70 (1.0) 535 (7.4) 6300 (87.3)
Married 205 (0.7) 440 (1.4) 220 (0.7) 1600 (5.1) 28 770 (92.1)
Family status
Couple only 25 (0.2) 100 (0.7) 65 (0.5) 410 (2.9) 13 815 (95.8)
One person 110 (1.1) 205 (2.0) 120 (1.1) 655 (6.3) 9230 (89.5)
Sole parent 145 (3.3) 245 (5.5) 125 (2.8) 540 (12.2) 3380 (76.3)
Couple with dependants 180 (0.9) 355 (1.8) 185 (0.9) 1280 (6.5) 17 730 (89.9)
Labour force status
Working 260 (0.8) 525 (1.6) 290 (0.9) 1890 (5.8) 29 690 (90.9)
Not working 205 (1.3) 375 (2.3) 200 (1.2) 995 (6.1) 14 460 (89.1)
NZ deprivation
Least deprived 165 (0.5) 355 (1.2) 180 (0.6) 1375 (4.5) 28 190 (93.1)
Medium deprived 125 (1.3) 200 (2.0) 145 (1.5) 680 (6.8) 8850 (88.5)
Most deprived 170 (2.0) 345 (4.0) 165 (1.9) 825 (9.6) 7110 (82.5)
NZ individual deprivation
0 55 (0.2) 155 (0.4) 140 (0.4) 1020 (2.9) 34 205 (96.1)
1–2 150 (1.4) 370 (3.6) 210 (2.0) 1170 (11.3) 8455 (81.7)
3–7 260 (8.7) 375 (12.7) 135 (4.6) 690 (23.4) 1495 (50.5)
Highest qualification
Degree or higher 50 (0.7) 60 (0.8) 50 (0.7) 305 (4.1) 6990 (93.8)
No qualification 135 (1.2) 260 (2.3) 150 (1.3) 765 (6.8) 9910 (88.3)
School qualification 85 (0.6) 205 (1.6) 125 (1.0) 760 (5.9) 11 810 (90.9)
Vocational qualification 195 (1.1) 370 (2.1) 160 (0.9) 1055 (6.1) 15 435 (89.7)
Age, in years
15–24 75 (1.0) 155 (2.0) 145 (1.8) 545 (6.9) 6975 (88.3)
25–64 375 (1.1) 715 (2.1) 320 (1.0) 2245 (6.7) 29 665 (89.0)
>64 10 (0.1) 30 (0.4) 20 (0.3) 95 (1.2) 7510 (98.0)
Sex
Male 130 (0.6) 235 (1.1) 170 (0.8) 935 (4.2) 20 820 (93.4)
Female 330 (1.2) 665 (2.5) 320 (1.2) 1950 (7.3) 23 335 (87.7)
Ethnicity
nMnPnA 285 (0.7) 550 (1.4) 265 (0.7) 1965 (5.0) 35 985 (92.2)
Māori 130 (2.4) 215 (3.9) 135 (2.4) 580 (10.5) 4435 (80.8)
Pacific 40 (2.1) 105 (5.4) 75 (3.7) 250 (12.8) 1480 (76.0)
Asian 10 (0.3) 30 (1.2) 20 (0.8) 90 (3.7) 2255 (93.8)
Total counts are rounded means.
*Two non-collections in two waves or three non-collections in three waves.
†Two non-collections in three waves.
‡One non-collection in two waves.
§One non-collection in three waves.
¶No non-collections in two or three waves.
nMnPnA, non-Māori non-Pacific non-Asian; SoFIE, Survey of Family, Income, and Employment.
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report non-collection of prescription medication, then
the true population relationship between prescription
deferral and declining health would be stronger than
found in this study. However, the collection–health
relationship in these ‘drop-outs’ would need to be very
different to the ‘stay-ins’ to change our conclusions.
As with other self-reported surveys, health status is
measured using self-reported data that rely on the ability
of respondents to recall information accurately. While
SRH is widely used in the social sciences, and is a well-
established and reliable instrument in cross-sectional
studies,34 35 its longitudinal reliability is less well-studied.
Thus in longitudinal studies, SRH may suffer from a
variety of biases, including measurement error, for
example, from ceiling effects.33
Strengths and weaknesses in relation to other studies
As mentioned in the introduction, few previous studies
have considered the health impact of not collecting pre-
scription drugs. Even fewer have provided longitudinal
evidence. This work extends findings from the previous
longitudinal study of Heisler et al,16 which had only
middle-aged or older adults and a shorter follow-up.
Our study included the total adult population over
15 years of age and had a longer follow-up (5 years).
Moreover, in Heisler et al,16 over half of those who
restricted medicine use because of cost had no insur-
ance coverage for medicines and therefore are likely to
have faced far higher prescription costs than those in
our study.
Our finding that non-collection of prescriptions had a
more significant effect on the health of males than
females, particularly in terms of mental health, has not
been reported previously. Another study using the same
data set found food insecurity had greater impacts on
mental health among women.36 Usually, females consult
general practitioners more frequently and take more
prescription medicines.37 38 It is possible that, on
average, the medicines that males take are more crucial
to maintaining their health status in the short to
medium term, and therefore deferral has a more dra-
matic effect. An alternative interpretation could be that,
within households, medicines for men are prioritised
over those for women. Such a pattern has been reported
for food within households in some developing coun-
tries.39 If this is the case, then not being able to afford
men’s medicines may indicate more severe financial
hardship. Further research is needed to confirm this
finding and explore these interpretations.
In our study, non-collection of prescription medicines
did not result in a decline in self-reported health among
elderly people, unlike Heisler et al.16 Non-collection of a
prescription item due to cost seems to be relatively
uncommon among the elderly in New Zealand (2% in
this study), probably because universal superannuation
ensures relatively low rates of poverty among the
elderly.40 Non-collection of prescription medication
could, therefore, be less commonly experienced by
those elderly people, making the effect on health
harder to measure, or perhaps high levels of prescribing
to the elderly means that drugs that do not affect their
(self-rated) health can be deferred.41 In contrast, rates
of poverty among young people (15–24 years) and the
working age population (25–64 years) are higher,42 and
people in these age groups are likely to face higher
charges for primary care. During the study period, extra-
funding was provided to primary health organisations to
reduce fees for those aged over 65 years from 2004,
while for those 18–65 years of age, the fee reduction was
introduced in tranches from 2005 to 2007.43 Therefore,
younger people who do not collect all their prescrip-
tions may defer more of them than elderly who do not
collect all of theirs.
Meaning of the study
The study findings increase understanding of the
importance of cost-related non-collection of prescrip-
tion drugs in the context of addressing and improving
the health of the population. Given the importance of
prescription medication in maintaining health and
treatment of acute and chronic illness, it is important to
design a co-payment regime that ensures that prescrip-
tions are affordable. Copayments in New Zealand are
low by international standards and the majority in each
of the waves did not report cost affecting not-collection
of prescription items. However, for the relatively small
subset of the population who did have to defer prescrip-
tion items, this resulted in poorer health. While only a
small proportion of the population reported non-
collection of prescription items due to cost, reporting
this in one wave means that there was a reasonable
probability (31.2%, table 3) of reporting it again in the
next wave. This suggests that some people were repeat-
edly unable to afford their prescriptions and, as dis-
cussed previously in relation to table 1, were therefore
likely to experience increasing ill-effects on their health.
Ensuring access to prescription medicines for this group
needs attention. While it is encouraging that in a
publicly-funded system only a small proportion of the
population was not collecting prescription medication,
it is important to note that even small prescription
Table 3 Empirical transition probabilities (%) computed
from counts of the number of times respondents reported
the indicated pair of prescription collection states in
successive observations over 3 waves
To (wave w+2)
From (w) Collection Non-Collection
Collection 97.4 2.6
Non-Collection 68.8 31.2
Transition probabilities were derived by dividing these counts by
row totals.
Transition probabilities between the same states are shown in
bold.
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Table 4 Estimates with 95% CIs from linear fixed effects regression models for three health outcomes
Characteristics
SRH PCS MCS
Estimate (CI) p Value Estimate (CI) p Value Estimate (CI) p Value
Collection status
Collection 1 1 1
Non-collection 0.11 (0.07 to 0.15) 0.00 000 −1.00 (−1.40 to −0.61) 0.00 000 −1.69 (−2.18 to −1.19) 0.00 000
Wave
3 1 1 1
5 0.07 (0.05 to 0.08) 0.00 000 0.03 (−0.11 to 0.16) 0.70 634 0.24 (0.08 to 0.41) 0.00 488
7 0.16 (0.14 to 0.17) 0.00 000 −0.66 (−0.80 to −0.51) 0.00 000 0.23 (0.05 to 0.41) 0.01 194
Marital status
Never married 1 1 1
Previously married −0.02 (−0.08 to 0.05) 0.62 482 −0.56 (−1.16 to 0.05) 0.07 313 −0.80 (−1.55 to −0.04) 0.03 903
Married 0.00 (−0.05 to 0.06) 0.88 864 −0.82 (−1.35 to −0.30) 0.00 224 0.75 (0.10 to 1.40) 0.02 466
Family type
Couple only 1 1 1
One person 0.01 (−0.03 to 0.06) 0.62 878 0.18 (−0.26 to 0.62) 0.42 776 −0.30 (−0.85 to 0.24) 0.27 493
Sole parent −0.04 (−0.10 to 0.03) 0.24 965 0.76 (0.15 to 1.38) 0.01 517 −0.23 (−0.99 to 0.53) 0.56 022
Couple with children −0.01 (−0.05 to 0.02) 0.48 955 0.05 (−0.29 to 0.40) 0.76 646 −0.06 (−0.49 to 0.37) 0.78 074
Labour force status
Employed 1 1 1
Not employed 0.05 (0.03 to 0.08) 0.00 018 −0.71 (−0.97 to −0.44) 0.00 000 −0.77 (−1.10 to −0.44) 0.00 000
NZDep (deprived)
Least 1 1 1
Middle −0.02 (−0.06 to 0.01) 0.20 890 0.23 (−0.12 to 0.58) 0.19 233 −0.13 (−0.57 to 0.30) 0.55 401
Most 0.03 (−0.01 to 0.07) 0.18 671 −0.06 (−0.48 to 0.36) 0.79 575 −0.56 (−1.08 to −0.04) 0.03 667
NZiDep (dep)
0 1 1 1
1–2 0.06 (0.03 to 0.08) 0.00 000 −0.12 (−0.34 to 0.10) 0.28 342 −1.27 (−1.54 to −0.99) 0.00 000
3–7 0.13 (0.09 to 0.17) 0.00 000 −0.64 (−1.07 to −0.21) 0.00 363 −3.24 (−3.77 to −2.71) 0.00 000
Education
Degree or higher 1 1 1
No education 0.02 (−0.09 to 0.12) 0.74 736 −0.66 (−1.66 to 0.34) 0.20 022 0.40 (−0.84 to 1.65) 0.52 918
School 0.05 (−0.03 to 0.14) 0.22 827 −0.17 (−0.99 to 0.65) 0.69 131 −0.72 (−1.74 to 0.29) 0.16 528
Postschool 0.02 (−0.07 to 0.11) 0.69 048 0.06 (−0.81 to 0.93) 0.89 149 0.01 (−1.07 to 1.10) 0.97 857
Main exposure was prescription collection status. p Values represent the significance of each covariate level.


















 on October 18, 2021 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2015-007781 on 9 November 2015. Downloaded from 
charges can have a deleterious effect on health. In
Quebec, Canada, the public insurer has eliminated
co-payments for people on low incomes and, as a result,
such people are more likely to pick up prescription
medicines.44
Governments and insurance companies in many coun-
tries are battling with increasing prescription medicine
expenditure. One common response has been to shift
costs on to patients and at the same time to discourage
‘unnecessary’ use by increasing prescription
charges.7 45–47 This study’s finding that even very modest
prescription charges lead to non-collection of prescrip-
tion medication that is associated with a measurable
decline in health status should be weighed against the
modest income the New Zealand government generates
from such charges. The New Zealand Treasury estimated
the recent increase in prescription charges from $3 to
$5 could lead to an additional $45–50 million in
revenue.48 Their discussion of the costs and benefits did
not include any potential negative health outcomes
from increasing charges: this study shows that these
could be significant. The increase in revenue from an
increase in copayments has to be weighed against the
evidence that higher copayment for prescription drugs
leads to reduction in demand for pharmaceuticals
(and/or increase in non-collection of prescription medi-
cation) with a simultaneous increase in the demand for
acute care,49 which may be more costly. Even a marginal
increase in non-collection of prescription medication is
likely to increase rates of poor health (and in a public
health system, higher costs for treatment elsewhere). For
example, Tamblyn et al8 found significant increases in
serious adverse events and emergency department visits
among elderly people and welfare recipients after the
introduction of cost-sharing in Quebec, Canada. The
additional revenue generated by an increase in prescrip-
tion charges could be partly or wholly offset by the cost
increase associated with higher hospitalisation and
demand for acute care.
Unanswered questions and future research
First, our study did not ask about the perceived need or
type of medication that was deferred because of cost.
Second, this study did not identify other reasons for
deferring prescription medicines, such as geographical
distance, or the cost of medical care for other family
members. Future research should also look at the accu-
mulated exposure to non-collection, that is, how many
prescription items or how many times one needs to not
collect prescription medication for it to have an effect
on health. More general models (eg, g-method estima-
tors) can provide unbiased results when there are
complex dynamics of evolving exposures and out-
comes,50–52 but such methods are beyond the scope of
this analysis, which focused on the association
between health and deferral of prescriptions net of
measured time-varying and unmeasured time-invariant
confounding.
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